首页/数据集/Equivalence evaluation of aggregation of AMP-glucagon vs. ELI-glucagon By SEC-HPLC.

Equivalence evaluation of aggregation of AMP-glucagon vs. ELI-glucagon By SEC-HPLC.

Figshare2024-05-21 更新2026-04-28 收录

数据链接：

https://figshare.com/articles/dataset/Equivalence_evaluation_of_aggregation_of_AMP-glucagon_vs_ELI-glucagon_By_SEC-HPLC_/25871536 数据链接链接失效反馈

官方服务：

资源简介：

Equivalence evaluation of aggregation of AMP-glucagon vs. ELI-glucagon By SEC-HPLC.

应用场景：

创建时间：

2024-05-21

药物生物等效性评估

体外方法

Background: Generic medicines must be therapeutic equivalents with the innovator brand before substitution is appropriate. Objective: This study was carried out to evaluate the in vitro equivalence

DataCite Commons2024-05-16 更新110

Number of significantly perturbed probes (q-value 1.3) when comparing sample groups.

差异表达分析

药物生物等效性评估

An initial set of 4176 probes was detected by comparing Copaxone and media groups. This set yielded significant differences between Glatopa and media and between nonequivalent glatiramoid ACN and glat

Figshare2015-12-03 更新30

Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic

药物生物等效性评估

比较转录组分析

For decades, policies regarding generic medicines have sought to provide patients with economical access to safe and effective drugs, while encouraging the development of new therapies. This balance i

NIAID Data Ecosystem30

Comparing the biological impact of glatiramer acetate with the biological impact of a generic.. Mus musculus

药物生物等效性评估

转录组药理学

NIAID Data Ecosystem50

The implementation of the bioequivalence certification policy in Chile: An analysis of market authorization data

药物生物等效性评估

仿制药政策评估

BackgroundAffordability is a key barrier to access to medicines. Generic medicines policies can address this barrier and promote access. Successful uptake of generic medicines depends, in part, on ens

Figshare2019-05-29 更新30

Equivalence evaluation of aggregation of AMP-glucagon vs. ELI-glucagon By SEC-HPLC.

资源简介：

相关数据集